Claire Woodley

London, ENG SE19RT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

The Management of Menopause in Women with Philadelphia-Negative Myeloproliferative Neoplasms: Clinical Challenges and Therapeutic Considerations.

The Management of Menopause in Women with Philadelphia-Negative Myeloproliferative Neoplasms: Clinical Challenges and Therapeutic Considerations.

Journal: Cancers

Published: January 29, 2026

Rapid and durable recovery of immune effector cells in myelofibrosis patients treated with momelotinib.

Rapid and durable recovery of immune effector cells in myelofibrosis patients treated with momelotinib.

Journal: Haematologica

Published: June 20, 2025

QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms.

QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms.

Journal: Leukemia

Published: March 19, 2025

Exploring perceptions in the management and treatment of polycythaemia vera in the UK.

Exploring perceptions in the management and treatment of polycythaemia vera in the UK.

Journal: Annals of hematology

Published: February 19, 2025

Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms.

Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms.

Journal: HemaSphere

Published: April 01, 2024

The management of myelofibrosis: A British Society for Haematology Guideline.

The management of myelofibrosis: A British Society for Haematology Guideline.

Journal: British journal of haematology

Published: August 15, 2023

Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.

Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.

Journal: British journal of haematology

Published: August 15, 2023

Advanced Systemic Mastocytosis with associated haematological neoplasm: Treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant.

Advanced Systemic Mastocytosis with associated haematological neoplasm: Treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant.

Journal: Current research in translational medicine

Published: May 24, 2023

Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders.

Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders.

Journal: Blood advances

Published: June 21, 2022

Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype.

Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype.

Journal: British journal of haematology

Published: April 09, 2022

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys).

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys).

Journal: Leukemia research reports

Published: March 04, 2022

Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.

Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.

Journal: Blood cancer journal

Published: January 28, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026